Insmed (NASDAQ:INSM) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Insmed (NASDAQ:INSM) in a report issued on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $105.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on INSM. Stifel Nicolaus lowered their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Bank of America boosted their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. UBS Group decreased their price objective on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Monday. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Insmed Stock Performance

NASDAQ:INSM opened at $65.71 on Tuesday. The company has a fifty day simple moving average of $72.17 and a two-hundred day simple moving average of $73.26. The company has a market cap of $11.95 billion, a price-to-earnings ratio of -11.75 and a beta of 0.84. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.06) EPS. As a group, equities analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. This represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. This represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 88,232 shares of company stock valued at $6,868,473. Insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. raised its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new position in Insmed during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its holdings in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed during the fourth quarter worth about $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.